Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma., PMID:40426305
Claudin 18 immunohistochemistry in cholangiocarcinoma., PMID:40386615
CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma., PMID:40206086
Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study., PMID:40200396
Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment., PMID:40128286
Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy., PMID:40117781
Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer., PMID:40115911
A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer., PMID:40019387
Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma., PMID:40015974
Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis., PMID:39947883
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models., PMID:39839455
Claudin 18.2 Expression in 1404 Digestive Tract Adenocarcinomas Including 1175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes Are Claudin 18.2 Positive., PMID:39826799
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature., PMID:39759684
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights., PMID:39753814
Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre., PMID:39731204
Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma., PMID:39727695
Efficacy and Safety of Zolbetuximab in Gastric Cancer., PMID:39699854
[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab]., PMID:39648123
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2., PMID:39637967
Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer., PMID:39572448
The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis., PMID:39461890
Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger., PMID:39364863
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art., PMID:39315517
Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets., PMID:39313274
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)., PMID:39301632
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer., PMID:39227365
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells., PMID:39187291
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting., PMID:39183320
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma., PMID:39171531
Variability in morphology and immunohistochemistry of Crohn's disease-associated small bowel neoplasms: implications of Claudin 18 and Cadherin 17 expression for tumor-targeted immunotherapies., PMID:39164422
[What's new in gastric cancer?]., PMID:39146748
Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach., PMID:39098518
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer., PMID:39095563
Zolbetuximab on the SPOTLIGHT-a light spot?, PMID:38988087
Zolbetuximab: First Approval., PMID:38967717
Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications., PMID:38949095
Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer., PMID:38926162
The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer., PMID:38919123
Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence., PMID:38917592
The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma., PMID:38884946
Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer., PMID:38843446
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results., PMID:38830992
Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models., PMID:38797537
Exploring various carbon nanomaterials-based electrodes modified with polymelamine for the reagentless electrochemical immunosensing of Claudin18.2., PMID:38761744
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies., PMID:38726797
Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse., PMID:38636191
New therapeutic target molecules for gastric and gastroesophageal junction cancer., PMID:38630383
68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients., PMID:38604764
DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy., PMID:38554200
Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer., PMID:38468289
For research use only. Not for human or drug use.
